OvaScience to Present at the Rodman & Renshaw/H.C. Wainwright Annual Global Investment Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–OvaScienceSM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, announced today that Company management will present
at the Rodman & Renshaw 17th Annual Global Investment
Conference, sponsored by H.C. Wainwright & Co., on Wednesday, September
9, 2015 at 12:05 pm ET at the St. Regis Hotel in New York City.

A live audio webcast of the presentation can be accessed by visiting the
Investors section of the Company’s website at www.ovascience.com.
A replay of the webcast will be archived on the OvaScience website for
two weeks following the presentation.

About OvaScience

OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to
improving treatment options for women around the world. OvaScience is
discovering, developing and commercializing new fertility treatments
because we believe women deserve more options. Each OvaScience treatment
is based on the Company’s proprietary technology platform that leverages
the breakthrough discovery of egg precursor (EggPCSM) cells –
immature egg cells found inside the protective ovarian lining. The
AUGMENTSM treatment, a fertility option specifically designed
to improve egg health, is available in certain IVF clinics in select
international regions outside of the United States. OvaScience is
developing the OvaPrimeSM treatment, which could increase a
woman’s egg reserve, and the OvaTureSM treatment, a potential
next-generation IVF treatment that could help a woman produce healthy,
young, fertilizable eggs without hormone injections. For more
information, please visit www.ovascience.com and
connect with us on Twitter
and Facebook.

Forward-Looking Statements

This press release includes forward-looking statements about the
Company’s plans for the AUGMENT treatment and two fertility treatments
in development. Actual results may differ materially from those
indicated by these forward-looking statements as a result of various
important factors, including risks related to: the possibility that
international IVF clinics that we work with may determine not to begin
or continue providing the AUGMENT treatment for commercial or other
reasons; our expectation that the AUGMENT treatment and OvaPrime
treatment meet the requirements of a class of products exempt from
premarket review and approval under applicable regulations in those
countries where we have launched or plan to introduce the AUGMENT
treatment and plan to introduce the OvaPrime treatment; the commercial
ramp up of the AUGMENT treatment, which we expect will depend upon
continued use of the AUGMENT treatment in our partner clinics in new and
existing regions, significant uptake in the UAE as a result of the
recent coverage, and other programs that include driving first-line use
of the AUGMENT treatment, and further results from ACE clinic experience
as they become available; the science underlying our treatment and
treatments in development (including the AUGMENT, OvaPrime and OvaTure
treatments), which is unproven; our ability to obtain regulatory
approval where necessary for our potential treatments; our ability to
develop our potential treatments, including the OvaPrime and OvaTure
treatments, on the timelines we expect, if at all; our ability to
commercialize the AUGMENT treatment and our potential treatments,
including the OvaPrime treatment, on the timelines we expect, if at all;
as well as those risks more fully discussed in the “Risk Factors”
section of our most recently filed Quarterly Report on Form 10-Q and/or
Annual Report on Form 10-K. The forward-looking statements contained in
this press release reflect our current views with respect to future
events. We anticipate that subsequent events and developments will cause
our views to change. However, while we may elect to update these
forward-looking statements in the future, we specifically disclaim any
obligation to do so. These forward-looking statements should not be
relied upon as representing our view as of any date subsequent to the
date hereof.



Theresa McNeely, 617-299-7356
Chief Communications Officer
Mayfield, 617-714-9638
Director, Corporate Communications